Publications by authors named "David Marcelino Sandoval Calderon"
Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial.
Jessica A Walsh Marina N Magrey Xenofon Baraliakos Kentaro Inui Meng-Yu Weng David Marcelino Sandoval Calderon
Arthritis Care Res (Hoboken)
March 2022
Article Synopsis
- The COAST-X trial assessed the impact of ixekizumab on functioning and health in patients with active nonradiographic axial spondyloarthritis over 52 weeks, comparing it to placebo.
- Ixekizumab treatment led to significant improvements in self-reported health scores, particularly in physical functioning, pain, and overall health status, with better results in patients receiving treatment every 2 weeks.
- Patients on ixekizumab reported notable enhancements in quality of life measures (EQ-5D-5L) compared to placebo, showing sustained benefits by week 52.